| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Biology |
Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid (UAM), 28006 Madrid, Spain [M. A. E-B., P. A., M. A-T., M. D. G., F. S-M., M. O. L.], and Departamento de Inmunología, Centro de Investigaciones Biológicas, Consejo Superior de Investigaciones Cientificas, 28006 Madrid, Spain [A. G-P.]
| ABSTRACT |
|---|
|
|
|---|
v integrins were increased in VHL(-) cells when compared with VHL(+) transfectants. Early after plating, both VHL(+) and VHL(-) cells were capable of assembling classic "patch-like"
v focal contacts. As the culture advanced and cells became confluent,
v integrins partly relocated to the intercellular junctions in VHL(+) transfectants, which then developed large ß1 fibrillar-type adhesions and anchored firmly to the substrate. In contrast, confluent VHL(-) cells were unable to assemble ß1 fibrillar adhesions, and
v focal contacts remained unchanged at all stages of the culture. Exogenous activation of ß1 integrins with either divalent cations or activating antibodies partly restored the capability of VHL(-) cells to assemble ß1 fibrillar adhesions and fibronectin fibers. Finally, pulse-chase studies of metabolically labeled 786-O cells revealed that the maturation of the common ß1-integrin chain was delayed in VHL(-) cells when compared with VHL(+) cells. Our results show that VHL is an important regulator of integrins and is essential for the formation of ß1 fibrillar adhesions. These findings help to explain the abnormal extracellular matrix organization and increased motility of VHL(-) renal cancer cells. | INTRODUCTION |
|---|
|
|
|---|
Integrins are a family of heterodimeric transmembrane proteins, composed of different
and ß chains, that provide a link between cells and the surrounding matrix through the formation of specialized structures called cell-matrix adhesions (12
, 13)
. The organization of cell-matrix adhesions is a strongly regulated process and requires the association of multiple proteins to the integrin-ligand complex. These proteins include vinculin, talin, and particularly, F-actin, which is essential for the stability of the whole complex (14
, 15)
. There are two major types of cell-matrix adhesions, namely classic FCs and fibrillar adhesions (16, 17, 18, 19)
, which not only differ in their morphology but also in their constituents. Classic FCs are arrowhead shaped, contain
v or ß1 integrins, and are rich in talin and vinculin. Conversely, fibrillar adhesions are elongated, contain exclusively ß1 integrins, and possess low levels of vinculin or talin. The formation of fibrillar adhesions involves cytoskeletal rearrangement of the previously formed ß1 classic FCs and is an absolute requirement for the organization of extracellular fibronectin into fibrillar arrays (20, 21, 22)
.
Our results show that the presence of VHL is strictly necessary for the formation of ß1-integrin fibrillar adhesions in renal cancer cells and may help to explain the altered ECM assembly and increased motility of VHL(-) cells.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Antibodies.
mAbs TS2/16 (23)
, LIA1/2 (23)
, HUTS21 (24)
, TS2/7 (anti-
1 integrin), Tea 1/41 (anti-
2 integrin), and VJ1/18 (anti-
3 integrin) have been described previously. mAb ABA-6D1 (anti-
v) and mAb P1D6 (anti-
5ß1) were provided by Dr. C. Martínez-Alonzo (Centro Nacional de Biotecnología, Madrid, Spain) and Dr. E. A. Wayner (Fred Hutchinson Cancer Research Center, Seattle, WA), respectively. Antifibronectin polyclonal antibody was purchased from Calbiochem, preimmune polyclonal antirabbit serum from Dako, and anti-
-tubulin and antivinculin mAbs from Sigma. The P3X63 myeloma protein was used as a control.
Flow Cytometry Analysis.
786-O cells (4.8 x 105) and RCC10 cells (4 x 105) were grown for 3 days and 36 h, respectively, in 35-mm culture dishes, trypsinized, washed, and resuspended in PBS. Cells were incubated with primary antibodies at 4°C for 30 min, washed, and incubated with FITC-conjugated antimouse immunoglobulins (DAKO-PATTS, Copenhagen, Denmark) for 30 min on ice. After being washed, cells were resuspended in PBS and analyzed in a FACScan flow cytometer (Becton Dickinson, Lincoln Park, NJ). To analyze the ß1-integrin activation state, cells were detached, treated with freshly prepared MnCl2 (1 mM), incubated with the primary antibody HUTS21 for 30 min at 37°C (24)
, and analyzed as described above.
Immunofluorescence Microscopy.
Cells were grown on glass coverslips in 24-well culture dishes, fixed at the indicated times with 3% paraformaldehyde in PBS for 15 min at room temperature, and washed with TBS (0.1 M Tris-HCl, 0.15 M NaCl). Cells were then permeabilized with 0.5% Triton X-100 for 10 min, and nonspecific binding sites were blocked by incubation with TNB (0.1 M Tris-HCl, 0.15 M NaCl, 0.5% blocking reagent; Boehringer Mannheim GmbH) for 30 min. Cells were incubated with the appropriate primary antibody for 45 min at room temperature and washed with TBS. Secondary antibodies, Alexa 488 goat antimouse IgG or Alexa 488 goat antirabbit IgG (Molecular Probes, Inc. Eugene, OR) were then added, and cells were incubated for 30 min. Finally, cells were washed with TBS, washed briefly with distilled water, and mounted with Mowiol. For double-label immunofluorescence studies, mouse serum was also used to prevent antibody cross-reactions. For F-actin double immunostaining, Texas red-phalloidin (Molecular Probes) was added to the appropriate secondary antibody. Samples were examined with a Nikon Labophot-2 photomicroscope, and images were acquired with a COHU high-performance CCD camera (Cohu, Tokyo, Japan) connected to a LEICA Q550 CW workstation (Leica Imaging Systems, Ltd. Cambridge, United Kingdom) using LEICA QFISH V1.01 Software (Leica).
Fibronectin-coated coverslips were prepared by incubation for at least 3 h at 37°C with a solution containing 10 µg/ml fibronectin (Sigma).
Measurement of the Strength of Cell Adherence.
786-O cells (125 x 103) were grown in 24-well dishes. After 1020 h, supernatants (250 µl) from P3X63, TS2/16, or LIA1/2 were added to the culture medium. After 34 days, the medium was removed, and a solution containing 1% Triton X-100 in PBS, which extracts noncytoskeletal-associated material, was added to intact monolayers. The time at which VHL(+) and VHL(-) cell monolayers were detached was measured. Cell detachment could be easily observed macroscopically, but was also verified with a phase-contrast microscope.
Western Blots.
786-O cells (1.4 x 106) were grown in 60-mm culture dishes for 34 days. To analyze total fibronectin, after one wash with PBS, cell monolayers were lysed for 15 min in RIPA buffer [150 mM NaCl, 10 mM Tris (pH 7.4), 1% NP40, 0.5% deoxycholate, and 0.1% SDS] supplemented with protease and phosphatase inhibitors. To quantify intracellular fibronectin, cells were mildly trypsinized, the reaction was stopped with fibronectin-free serum, and cells were washed three times with excess RPMI before lysis in RIPA buffer. Cell lysates were harvested and centrifuged for 20 min at 14,000 rpm and 4°C. Protein concentrations were determined using the BIO-RAD Dc Protein Assay Kit, and equal amounts of lysates were subjected to SDS-PAGE electrophoresis, transferred to a nitrocellulose membrane (Bio-Rad), and finally blotted with the indicated antibody. Immunodetection was performed using enhanced chemiluminescence (Amersham, Arlington Heights, IL).
Pulse-Chase Experiments.
Pulse-chase labeling of cells with [35S]methionine was carried out as described in Current Protocols in Immunology (25)
and as described by others (26, 27, 28)
. 786-O cells (clones WT8 and MUT1-115) were plated in 150-mm dishes 1 day before the experiment. Monolayers at 7090% confluence were then washed with HBSS (BioWhittaker Europe, Verniers, Belgium). Labeling medium [RPMI without methionine (Sigma), 5% dialyzed FCS, and 2 mM L-glutamine] was added to the dishes and incubated for 2 h at 37°C to deplete intracellular pools of methionine. After this medium was removed, 6 ml of labeling medium and 1.0 mCi of [35S]methionine were added to each dish, and cells were incubated at 37°C for 30 min to allow the incorporation of radioactive methionine to biosynthetic precursors. The monolayers were washed with chase medium [RPMI, 10% FCS, and 15 mg/liter nonradioactive L-methionine (Sigma)]. Maturation of labeled precursors was followed by lysis at different chase times. At each chase time, monolayers were scraped off and centrifuged for 5 min at 14,000 rpm and 4°C. After being washed with PBS, pellets were lysed in EBC buffer [50 mM Tris (pH 8.0), 120 mM NaCl, 0.5% NP40] supplemented with protease and phosphatase inhibitors and clarified by centrifugation at 14,000 rpm for 15 min. Supernatants were then precleared with protein G-Sepharose, and equal amounts of radioactive lysates were incubated with the appropriate antibody coupled to protein G-Sepharose at 4°C under continuous mixing. Immunoprecipitates were washed with EBC buffer and PBS and boiled for 5 min in Laemmli buffer under nonreducing conditions; samples were run in 7% SDS-PAGE. Gels were fixed and treated with Amplify (Amersham Pharmacia Biotech, Little Chalfont, Buckinghamshire, United Kingdom), dried under vacuum at 60°C for 2 h, and exposed to an X-ray film at -80°C.
125I Labeling of Cell Surface Proteins.
To analyze cell surface integrins, cell monolayers (one 150-mm dish at 7090% confluence, plated 1 day before the experiment) were harvested and washed in PBS by centrifugation for 5 min at 1200 rpm. Cells were then iodinated for 25 min with 1 mCi of sodium [125I]iodine (Amersham Pharmacia Biotech) using 1,3,4,6-tetrachloro-3
,6
-diphenylglycoluril (IODO-GEN; Pierce). This compound selectively catalyzes the addition of radioiodine to the tyrosine residues exclusively on the outside of the cell membrane (29)
. The iodination reaction was stopped by incubating cells with PBS supplemented with 0.4% L-tyrosine (Sigma). After being washed twice with PBS, cells were lysed with EBC buffer, and equal amounts of radioactive lysates were subjected to immunoprecipitation as above.
| RESULTS |
|---|
|
|
|---|
To test this hypothesis, we cultured 786-O cells on coverslips in the presence or absence of an excess of normal fibronectin. Although the addition of normal fibronectin to the culture dish increased matrix assembly in VHL(+) cells, we did not detect any enhancement in VHL(-) cells (Fig. 1A)
. Likewise, culturing VHL(-) cells on fibronectin-coated coverslips did not significantly induce the assembly of fibronectin fibers. These results suggest that the defect in matrix formation might not be caused by the secretion of an altered form of fibronectin; otherwise, competition by exogenous fibronectin should have reversed the defect. Additionally, to rule out the possibility that fibronectin is abnormally accumulated inside VHL(-) cells, we quantified intracellular and total (extracellular and intracellular) fibronectin. To measure total fibronectin, we lysed VHL(+) and VHL(-) cells in their own culture dishes and then analyzed them by Western blotting. This method does not discriminate between assembled and surface adhered but nonassembled fibronectin. As shown in Fig. 1B
, there were minimal differences in total fibronectin levels between VHL(+) and VHL(-) cells. Parallel mild trypsinization and washing of cell monolayers, a procedure that removes the ECM (30)
, was used to quantify exclusively intracellular fibronectin. Notably, the amount of intracellular fibronectin did not significantly differ between VHL(+) and VHL(-) cells (Fig. 1B)
.
|
v,
3, and ß1 were clearly up-regulated in VHL(-) cells compared with VHL(+) cells (Fig. 2)
2 and
5 integrins were also augmented in VHL(-) cells, but their expression was low when compared with
3, particularly in RCC10 cells. Finally, no expression of
1,
4, and
6 integrins was detected in either renal cancer cell lines (data not shown).
|
5ß1 (17
, 32)
, although under certain circumstances other integrins have been involved. Our results indicate that the altered fibronectin assembly of VHL(-) renal cancer cells is not attributable to a decrease in ß1 integrins on the cell surface. In addition, because we observed comparable increases in ß1,
3,
v, and to a lesser extent,
2 and
5 integrins in both VHL(-) 786-O and RCC10 renal cancer cells, we propose that these changes may be a general consequence of VHL inactivation.
VHL Regulates Assembly of ß1 Fibrillar Adhesions in Renal Cancer Cells.
To explore different mechanisms by which VHL could modulate fibronectin assembly, we next analyzed the effects of VHL expression on the formation of cell-matrix adhesions in renal cancer cells. For this purpose, 786-O cells were cultured on coverslips and analyzed at different culture time points by immunofluorescence microscopy. To stain ß1 integrins, we used the monoclonal antibody HUTS21, which selectively recognizes activated ß1 integrins and is an excellent marker for ß1 cell-matrix adhesions (24
, 33)
.
Early after plating (1015 h), both VHL(+) and VHL(-) cells adopted a fibroblastic-like morphology and assembled classic "patch-like"
v FCs (Fig. 3)
, which were coincident with the termini of actin stress fibers. Vinculin, which is an intracellular constituent of the classic FC complex, showed a similar pattern of arrowhead-shaped patches in both groups of cells. Under the conditions tested, ß1 classic FCs were poor or absent at this early stage of culture and activated ß1 integrins and fibronectin displayed a diffuse but coincident distribution in both VHL(+) and (-) cells (Fig. 3)
.
|
v integrins partly relocated to the intercellular junctions (Fig. 4A
5ß1 showed a very similar pattern of fibrillar adhesions in VHL(+) cells (Fig. 4B)
|
v classic FCs (Fig. 4A
5ß1 integrins were diffusely distributed in VHL(-) cells.
To determine whether the formation of ß1-integrin fibrillar adhesions in VHL(+) cells results in firmer cell adhesion to the substrate, 786-O cells were cultured for several days in the presence of either ß1-activating (TS2/16) or ß1-blocking (LIA1/2) antibodies. The medium was then removed, and intact monolayers were treated with a solution containing 1% Triton X-100, which rapidly extracts noncytoskeletal-associated material and promotes cell detachment. As shown in Fig. 5
, whereas VHL(-) cells detached almost immediately, VHL(+) cells required a much more prolonged incubation time. Interestingly, blockage of ß1 integrin function and fibronectin assembly in VHL(+) 786-O cells with the antibody LIA1/2 (see below; Fig. 6B
) dramatically reduced the time of detachment, which was then very similar to that of VHL(-) cells. On the other hand, the ß1-activating antibody TS2/16, which increases the formation of ß1 fibrillar adhesions and fibronectin fibrils (see below; Fig. 6B
) prolonged the time of detachment of VHL(+) monolayers but had no effect on that of VHL(-) cells.
|
|
Outside-In Activation of ß1 Integrins Stimulates Fibronectin Assembly in VHL(-) Cells.
The ability of integrins to mediate fibronectin organization depends on their state of activation (34)
. Integrin activation is regulated by signals from inside the cell and can also be easily increased from outside with MnCl2 or with activating antibodies (12
, 13)
. To measure the integrin activation state in 786-O cells, we performed flow cytometry analysis with the antiactivated ß1-integrin antibody HUTS21, and no significant differences between VHL(+) and VHL(-) cells were detected (Fig. 6A)
. Likewise, a short incubation with MnCl2 before analysis increased ß1-integrin activation very similarly in both groups of cells. Notably, when VHL(-) cells were cultured in the sustained presence of either the ß1-activating antibody TS2/16 (Refs. 23
, 35
; Fig. 6B
) or MnCl2 (data not shown), an increase in fibronectin fibers was detected by immunofluorescence microscopy. This increment in matrix assembly, although modest, supports the notion that inappropriate ß1-integrin function could play a role in the abnormal organization of ß1 fibrillar adhesions and fibronectin fibers in VHL(-) cells. Finally, culturing of VHL(+) cells with the ß1-blocking antibody LIA1/2 (23)
completely abrogated the formation of fibronectin fibers (Fig. 6B)
, demonstrating that fibronectin assembly in 786-O renal cancer cells is completely dependent on ß1 integrins (20
, 36)
.
Biosynthetic Maturation of ß1 Integrins Is Delayed in VHL(-) Cells.
Immature precursors of the different
- and common ß1-integrin chains associate in the endoplasmic reticulum, where they are driven to the Golgi apparatus for further glycosylation and processing (37)
. Mature heterodimeric integrins are then translocated to the cell membrane, where they subsequently become functional. To determine whether the biosynthesis of ß1 integrins could be affected in VHL(-) cells, we performed pulse-chase analysis of ß1 integrins in metabolically labeled 786-O cells. Four bands could be typically observed in these experiments, representing ß1 and associated
chains in different stages of maturation. Iodination of cell surface proteins was used to discriminate mature from immature integrin subunits (38)
. Interestingly, when compared with their VHL(+) counterparts, VHL(-) cells presented a significant delay in the maturation of the common ß1-integrin chain during the first hours (Fig. 7)
. A comparable delay in ß1-chain biosynthesis was also observed when
5ß1 integrins were immunoprecipitated (data not shown). However,
-chain maturation was unaffected in any case, showing that the defect is restricted to the ß1 chain. Because the formation of integrin fibrillar adhesions is a dynamic process, a delay in the maturation of ß1 integrins could affect the rate of assembly and maintenance of this complex. However, the organization of ß1 fibrillar adhesions in VHL(+) 786-O cells is a slow process, and mature integrin surface levels are increased even in VHL(-) cells. Thus, the relative contribution of this delayed maturation to the defective matrix assembly may be modest.
|
| DISCUSSION |
|---|
|
|
|---|
3, ß1,
v, and to a lesser extent,
2 and
5 integrins are up-regulated in VHL(-) cells demonstrate that the altered assembly of the fibronectin matrix is not attributable to decreased integrin expression. These results are also clearly consistent with the highly migratory phenotype that has been reported previously in VHL(-) cells (9)
.
Comparison of ß1 and
v cell-matrix adhesions in VHL(+) and VHL(-) renal cancer cells at different stages of culture provides important clues concerning their distinct fibronectin matrix organization and migratory behavior. Early after plating, both VHL(+) and VHL(-) cells display proper
v classic FCs and patches of vinculin, but lack ß1 fibrillar adhesions. However, as the culture advances and cells become confluent, VHL(+) transfectants progressively assemble large ß1 fibrillar adhesions, and
v integrins partly relocate to the intercellular junctions. The presence of ß1-integrin fibrillar adhesions in VHL(+) cells at late confluence allows them to firmly anchor to the substrate and might be an important mechanism in controlling cell migration. In contrast, late confluent VHL(-) cells are not capable of organizing adequate ß1 fibrillar adhesions or fibronectin fibers and show weaker attachment to the substrate. The failure of the ß1-activating antibody TS2/16 to delay the detachment of VHL(-) cells treated with Triton X-100 (see Fig. 5
) contrasts with its effect of improving matrix assembly in the same cells. However, this improvement is modest when compared with fibronectin matrix assembly in VHL(+) cells.
VHL(-) cells displayed adequate
v classic FCs at any stage of culture. This implies that there is no general failure in the assembly of cell-matrix adhesions in VHL(-) cells and demonstrates that the defect is restricted exclusively to ß1 fibrillar adhesions. In this regard, a recent report by Kamada et al. (39)
showed that the organization of vinculin, an intracellular constituent of classic FCs, is diminished in VHL(-) UMRC6 cells compared with VHL(+) transfectants. Accordingly, the authors concluded that the formation of FCs was impaired in VHL(-) cells. However, in most adherent cells, vinculin distribution is not fully restricted to cell-matrix adhesions, and in their study, Kamada et al. (39)
did not analyze the subcellular distribution of
v and ß1 integrins, which are much more specific markers for classic FCs and fibrillar adhesions. Differences between both studies could be attributable to the cell type used.
The restored ability of VHL(+) transfectants to assemble extracellular fibronectin is mediated by ß1 integrins: it is completely abrogated by ß1-blocking antibodies. We propose that an abnormal organization of ß1 fibrillar adhesions could help to explain the deficient fibronectin assembly of VHL(-) cells. Nevertheless, we cannot formally rule out the possibility that an undetectable amount of abnormal fibronectin is accumulated and secreted in VHL(-) cells, interfering with normal fibronectin assembly.
How does VHL regulate the formation of ß1 fibrillar adhesions and subsequent fibronectin organization? VHL could regulate the expression or function of any of the intracellular constituents of the fibrillar adhesion. In this regard, tensin, which has been implicated in the translocation of ß1 integrins from the classic FC to the mature fibrillar adhesion (17) , is an excellent candidate to be regulated by VHL. In addition, VHL could be modulating other proteins, such as the small GTP-binding proteins Rho, Rac, and cdc42, which play an important role in the control of cytoskeleton and regulate the formation of cell-matrix adhesions (40) . These possibilities are being addressed at present.
In conclusion, this report shows that, in renal cancer cells, the presence of VHL is required for the adequate assembly of ß1-integrin fibrillar adhesions and demonstrates that VHL controls the strength of cell adhesion through this mechanism. The failure of VHL(-) cells to organize ß1 fibrillar adhesions could explain their abnormal matrix assembly and may play a role in their highly migratory phenotype.
| ACKNOWLEDGMENTS |
|---|
| FOOTNOTES |
|---|
1 This work was supported by Grants SAF2001/0215 and FEDER-2FD971870 from the Ministerio de Educación y Cultura. Miguel A. Esteban-Barragán, Miguel Álvarez-Tejado, and M. Dolores Gutiérrez were supported by fellowships from Comunidad Autónoma de Madrid. ![]()
2 To whom requests for reprints should be addressed, at Servicio de Inmunología, Hospital de la Princesa, Diego de León 62, Madrid 28006, Spain. Phone: 34-91-5202662; Fax: 34-91-5202374; E-mail: mortiz{at}hlpr.insalud.es ![]()
3 The abbreviations used are: VHL, von Hippel-Lindau; ECM, extracellular matrix; FC, focal contact; mAb, monoclonal antibody; TBS, Tris-buffered saline. ![]()
Received 8/13/01. Accepted 3/19/02.
| REFERENCES |
|---|
|
|
|---|
(5)ß(1) integrins promotes early fibronectin fibrillogenesis. J. Cell Biol., 148: 1075-1090, 2000.
,6
-diphenylglycoluril. Biochemistry, 17: 4807-4817, 1978.[Medline]
5/ß1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation. Mol. Biol. Cell, 11: 2485-2496, 2000.
3 integrin/tetraspanin complexes in the angiogenic response induced by angiotensin II. FASEB J., 15: 1457-1459, 2001.
5ß1-mediated signaling pathways by fibronectins cell adhesion and matrix assembly domains. J. Cell Biol., 141: 241-253, 1998.
5ß1 integrin. J. Cell Sci., 108: 3317-3329, 1995.[Abstract]
This article has been cited by other articles:
![]() |
I. Wacker, M. Sachs, K. Knaup, M. Wiesener, J. Weiske, O. Huber, Z. Akcetin, and J. Behrens Key Role for Activin B in Cellular Transformation after Loss of the von Hippel-Lindau Tumor Suppressor Mol. Cell. Biol., April 1, 2009; 29(7): 1707 - 1718. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Feijoo-Cuaresma, F. Mendez, A. Maqueda, M. A. Esteban, S. Naranjo-Suarez, M. C. Castellanos, M. H. del Cerro, S. N. Vazquez, A. Garcia-Pardo, M. O. Landazuri, et al. Inadequate Activation of the GTPase RhoA Contributes to the Lack of Fibronectin Matrix Assembly in von Hippel-Lindau Protein-defective Renal Cancer Cells J. Biol. Chem., September 5, 2008; 283(36): 24982 - 24990. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. R. Chintalapudi, M. Markiewicz, N. Kose, V. Dammai, K. J. Champion, R. S. Hoda, M. Trojanowska, and T. Hsu Cyr61/CCN1 and CTGF/CCN2 mediate the proangiogenic activity of VHL-mutant renal carcinoma cells Carcinogenesis, April 1, 2008; 29(4): 696 - 703. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. L. Wu, H. Miao, and S. Khan JAK kinases promote invasiveness in VHL-mediated renal cell carcinoma by a suppressor of cytokine signaling-regulated, HIF-independent mechanism Am J Physiol Renal Physiol, December 1, 2007; 293(6): F1836 - F1846. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Costa and H. A. Drabkin Renal Cell Carcinoma: New Developments in Molecular Biology and Potential for Targeted Therapies Oncologist, December 1, 2007; 12(12): 1404 - 1415. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Grosfeld, I. P. Stolze, M. E. Cockman, C. W. Pugh, M. Edelmann, B. Kessler, A. N. Bullock, P. J. Ratcliffe, and N. Masson Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor J. Biol. Chem., May 4, 2007; 282(18): 13264 - 13269. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Esteban, S. K. Harten, M. G. Tran, and P. H. Maxwell Formation of Primary Cilia in the Renal Epithelium Is Regulated by the von Hippel-Lindau Tumor Suppressor Protein J. Am. Soc. Nephrol., July 1, 2006; 17(7): 1801 - 1806. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Hsu, Y. Adereth, N. Kose, and V. Dammai Endocytic Function of von Hippel-Lindau Tumor Suppressor Protein Regulates Surface Localization of Fibroblast Growth Factor Receptor 1 and Cell Motility J. Biol. Chem., April 28, 2006; 281(17): 12069 - 12080. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Tang, F. Mack, V. H. Haase, M. C. Simon, and R. S. Johnson pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition. Mol. Cell. Biol., April 1, 2006; 26(7): 2519 - 2530. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Esteban, M. G.B. Tran, S. K. Harten, P. Hill, M. C. Castellanos, A. Chandra, R. Raval, T. S. O'Brien, and P. H. Maxwell Regulation of E-cadherin Expression by VHL and Hypoxia-Inducible Factor. Cancer Res., April 1, 2006; 66(7): 3567 - 3575. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. J. Calzada, M. A. Esteban, M. Feijoo-Cuaresma, M. C. Castellanos, S. Naranjo-Suarez, E. Temes, F. Mendez, M. Yanez-Mo, M. Ohh, and M. O. Landazuri von Hippel-Lindau Tumor Suppressor Protein Regulates the Assembly of Intercellular Junctions in Renal Cancer Cells through Hypoxia-Inducible Factor-Independent Mechanisms Cancer Res., February 1, 2006; 66(3): 1553 - 1560. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Nakamura, P. Abreu-e-Lima, Y. Awakura, T. Inoue, T. Kamoto, O. Ogawa, H. Kotani, T. Manabe, G.-J. Zhang, K. Kondo, et al. Clusterin Is a Secreted Marker for a Hypoxia-Inducible Factor-Independent Function of the von Hippel-Lindau Tumor Suppressor Protein Am. J. Pathol., February 1, 2006; 168(2): 574 - 584. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. I. Zhou, R. L. Foy, V. C. Chitalia, J. Zhao, M. V. Panchenko, H. Wang, and H. T. Cohen Jade-1, a candidate renal tumor suppressor that promotes apoptosis PNAS, August 2, 2005; 102(31): 11035 - 11040. [Abstract] [Full Text] [PDF] |
||||
![]() |
W.G. KAELIN JR. The von Hippel-Lindau Tumor Suppressor Protein: Roles in Cancer and Oxygen Sensing Cold Spring Harb Symp Quant Biol, January 1, 2005; 70(0): 159 - 166. [Abstract] [PDF] |
||||
![]() |
W. Y. Kim and W. G. Kaelin Role of VHL Gene Mutation in Human Cancer J. Clin. Oncol., December 15, 2004; 22(24): 4991 - 5004. [Abstract] [Full Text] [PDF] |
||||
![]() |
G Eisenhofer, T-T Huynh, K Pacak, F M Brouwers, M M Walther, W M Linehan, P J Munson, M Mannelli, D S Goldstein, and A G Elkahloun Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome Endocr. Relat. Cancer, December 1, 2004; 11(4): 897 - 911. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. I. Sufan, M. A. S. Jewett, and M. Ohh The role of von Hippel-Lindau tumor suppressor protein and hypoxia in renal clear cell carcinoma Am J Physiol Renal Physiol, July 1, 2004; 287(1): F1 - F6. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Sutovsky and E. Gazit The von Hippel-Lindau Tumor Suppressor Protein Is a Molten Globule under Native Conditions: IMPLICATIONS FOR ITS PHYSIOLOGICAL ACTIVITIES J. Biol. Chem., April 23, 2004; 279(17): 17190 - 17196. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Qi and M. Ohh The von Hippel-Lindau Tumor Suppressor Protein Sensitizes Renal Cell Carcinoma Cells to Tumor Necrosis Factor-Induced Cytotoxicity By Suppressing the Nuclear Factor-{kappa}B-Dependent Antiapoptotic Pathway Cancer Res., November 1, 2003; 63(21): 7076 - 7080. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. G. Kaelin Jr. The von Hippel-Lindau Gene, Kidney Cancer, and Oxygen Sensing J. Am. Soc. Nephrol., November 1, 2003; 14(11): 2703 - 2711. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Galban, J. L. Martindale, K. Mazan-Mamczarz, I. Lopez de Silanes, J. Fan, W. Wang, J. Decker, and M. Gorospe Influence of the RNA-Binding Protein HuR in pVHL-Regulated p53 Expression in Renal Carcinoma Cells Mol. Cell. Biol., October 15, 2003; 23(20): 7083 - 7095. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |